Merck and Gilead have combined their drugs islatravir and lenacapavir to develop what could soon become the first long-acting oral HIV treatment that can be taken weekly. (SvetaZi/iStock/Getty Images ...
Your browser does not support the audio element.
June 3 (Reuters) – Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly, worth up to $1.9 billion, to develop new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results